203 related articles for article (PubMed ID: 26122186)
1. Lung cancer: Squiring immunotherapy to CheckMate.
Hutchinson L
Nat Rev Clin Oncol; 2015 Aug; 12(8):436. PubMed ID: 26122186
[No Abstract] [Full Text] [Related]
2. Balancing Benefit, Risk, and Time to New Cancer Therapies.
West HJ
JAMA Oncol; 2016 Jan; 2(1):122. PubMed ID: 26468768
[No Abstract] [Full Text] [Related]
3. PD-L1 in non-small-cell lung cancer: the third target for immunotherapy.
Smit EF; van den Heuvel MM
Lancet; 2016 Apr; 387(10030):1795-6. PubMed ID: 26972842
[No Abstract] [Full Text] [Related]
4. Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?
Mok TSK; Loong HH
Lancet; 2016 Apr; 387(10027):1488-1490. PubMed ID: 26712085
[No Abstract] [Full Text] [Related]
5. Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression.
Kunimasa K; Nakamura H; Nishino K; Nakatsuka SI; Kumagai T
J Thorac Oncol; 2019 Oct; 14(10):e231-e233. PubMed ID: 31558236
[No Abstract] [Full Text] [Related]
6. Nedaplatin: a new platinum for squamous lung cancer?
Wu Y; Spicer J
Lancet Oncol; 2015 Dec; 16(16):1573-4. PubMed ID: 26522336
[No Abstract] [Full Text] [Related]
7. Immunotherapy: pembrolizumab-is the writing on the wall for cancer?
Hutchinson L
Nat Rev Clin Oncol; 2015 Jul; 12(7):371. PubMed ID: 25963092
[No Abstract] [Full Text] [Related]
8. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
9. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.
Matter-Walstra K; Schwenkglenks M; Aebi S; Dedes K; Diebold J; Pietrini M; Klingbiel D; von Moos R; Gautschi O;
J Thorac Oncol; 2016 Nov; 11(11):1846-1855. PubMed ID: 27311996
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab May Work as First-Line NSCLC Therapy.
Cancer Discov; 2016 Sep; 6(9):OF2. PubMed ID: 27466254
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
Gyawali B; Ota A; Ando Y
N Engl J Med; 2016 Feb; 374(5):493. PubMed ID: 26840146
[No Abstract] [Full Text] [Related]
12. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
Hasegawa T; Uno H; Wei LJ
N Engl J Med; 2016 Feb; 374(5):492-3. PubMed ID: 26840145
[No Abstract] [Full Text] [Related]
13. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
Borghaei H; Brahmer J
N Engl J Med; 2016 Feb; 374(5):493-4. PubMed ID: 26840144
[No Abstract] [Full Text] [Related]
14. Immunotherapy in Lung Cancer.
Du L; Herbst RS; Morgensztern D
Hematol Oncol Clin North Am; 2017 Feb; 31(1):131-141. PubMed ID: 27912829
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab--an effective second-line treatment for NSCLC.
Romero D
Nat Rev Clin Oncol; 2015 Dec; 12(12):685. PubMed ID: 26483299
[No Abstract] [Full Text] [Related]
16. Immunotherapy for non-small cell lung cancer.
Vafadar S
JAAPA; 2019 Sep; 32(9):37-42. PubMed ID: 31460972
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Horn L; Spigel DR; Vokes EE; Holgado E; Ready N; Steins M; Poddubskaya E; Borghaei H; Felip E; Paz-Ares L; Pluzanski A; Reckamp KL; Burgio MA; Kohlhäeufl M; Waterhouse D; Barlesi F; Antonia S; Arrieta O; Fayette J; Crinò L; Rizvi N; Reck M; Hellmann MD; Geese WJ; Li A; Blackwood-Chirchir A; Healey D; Brahmer J; Eberhardt WEE
J Clin Oncol; 2017 Dec; 35(35):3924-3933. PubMed ID: 29023213
[TBL] [Abstract][Full Text] [Related]
19. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
20. Reply to G. Spitzer and M.A. Socinski.
Zer A; Leighl NB
J Clin Oncol; 2015 Feb; 33(5):525-6. PubMed ID: 25584009
[No Abstract] [Full Text] [Related]
[Next] [New Search]
